ISO 10993-17:2023
Biological evaluation of medical devices — Part 17: Toxicological risk assessment of medical device constituents
This document specifies the process and requirements for the toxicological risk assessment of medical device constituents. The methods and criteria used to assess whether exposure to a constituent is without appreciable harm are also specified. The toxicological risk assessment can be part of the biological evaluation of the final product, as described in ISO 10993-1.
The process described in this document applies to chemical characterization information obtained in line with ISO 10993-18. When a toxicological risk assessment of either the compositional information or analytical chemistry data (e.g. extractable data or leachable data) are required to determine whether the toxicological risks related to the constituents are negligible or tolerable.
The process described in this document is not intended to apply to circumstances where the toxicological risk has been estimated by other means, such as:
— constituents, excluding cohort of concern or excluded chemicals, that are present in or extracted from a medical device at an amount representative of patient exposure below a relevant, toxicologically-based reporting threshold (see applicable requirements in ISO 10993-18:2020, Annex E and ISO/TS 21726);
— a new or changed medical device for which chemical or biological equivalence has been established with an existing biocompatible or clinically established medical device (see applicable requirements in ISO
Get this standard
Prices exclude GST
PDF
( Single user document)
HardCopy
Networkable PDF
Foreword
Introduction
1 Scope
2 Normative references
3 Terms and definitions
4 Abbreviated terms and symbols
5 Toxicological risk assessment within the biological evaluation process
5.1 General
5.1.1 Risk assessment principles
5.1.2 Hazard identification
5.1.3 Risk estimation
5.2 Toxicological risk assessment process
6 Constituent specific toxicological information
6.1 General
6.2 Identification of hazardous constituents
6.2.1 General
6.2.2 Application of the toxicological screening limit
6.2.3 Identification of human carcinogens or suspected human carcinogens
6.2.4 Selection of the point of departure
7 Tolerable contact level, tolerable intake and threshold of toxicological concern
7.1 Derivation of TCL and TI
7.2 Application of TTC
8 Exposure dose estimation
9 Margin of safety
9.1 General
9.2 Calculating the margin of safety
9.2.1 General
9.2.2 Combining MoS values to address additivity of harm
10 Toxicological risk acceptance criteria
10.1 General
10.2 Further risk analysis or risk evaluation or risk control
11 Reporting requirements
Annex A (normative) Evaluation of toxicological data quality when selecting a point of departure
Annex B (normative) Derivation of toxicological screening limits
Annex C (normative) Derivation of constituent TI or TCL for select endpoints
Annex D (informative) Typical assumptions for biological parameters
Annex E (normative) Estimation of an exposure dose
Annex F (informative) Reporting of toxicological risk assessment information
Bibliography
Previous versions
Keep me up-to-date
Sign up to receive updates when there are changes to this standard
Related Information
Similar Standards
-
BS EN ISO 10993-1:2020
Biological evaluation of medical devices, Evaluation and testing within a risk management process
-
BS EN ISO 10993-1:2020 - TC
Tracked Changes. Biological evaluation of medical devices, Evaluation and testing within a risk management process
-
BS EN ISO 10993-10:2023
Biological evaluation of medical devices, Tests for skin sensitization
-
BS EN ISO 10993-10:2023 - TC
Tracked changes. Biological evaluation of medical devices, Tests for skin sensitization
Foreword
Introduction
1 Scope
2 Normative references
3 Terms and definitions
4 Abbreviated terms and symbols
5 Toxicological risk assessment within the biological evaluation process
5.1 General
5.1.1 Risk assessment principles
5.1.2 Hazard identification
5.1.3 Risk estimation
5.2 Toxicological risk assessment process
6 Constituent specific toxicological information
6.1 General
6.2 Identification of hazardous constituents
6.2.1 General
6.2.2 Application of the toxicological screening limit
6.2.3 Identification of human carcinogens or suspected human carcinogens
6.2.4 Selection of the point of departure
7 Tolerable contact level, tolerable intake and threshold of toxicological concern
7.1 Derivation of TCL and TI
7.2 Application of TTC
8 Exposure dose estimation
9 Margin of safety
9.1 General
9.2 Calculating the margin of safety
9.2.1 General
9.2.2 Combining MoS values to address additivity of harm
10 Toxicological risk acceptance criteria
10.1 General
10.2 Further risk analysis or risk evaluation or risk control
11 Reporting requirements
Annex A (normative) Evaluation of toxicological data quality when selecting a point of departure
Annex B (normative) Derivation of toxicological screening limits
Annex C (normative) Derivation of constituent TI or TCL for select endpoints
Annex D (informative) Typical assumptions for biological parameters
Annex E (normative) Estimation of an exposure dose
Annex F (informative) Reporting of toxicological risk assessment information
Bibliography